临床特征和年轻发病多重系统缩的结果
Negin Badihian1, Rodolfo Savica1, Charles H Adler2
1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Movement disorders clinical practice
|March 12, 2024
概括
年轻发作的多系统缩 (YOMSA) 与典型的MSA有共同的特征,但往往会延迟诊断. 在YOMSA患者中,早期自主性衰竭表明生存前景较差.
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
- 临床医学 临床医学
背景情况:
- 年轻发病的多系统缩 (YOMSA) 被定义为40岁之前发病的多系统缩 (MSA).
- YOMSA是罕见的,对其特定的表型和自然历史的理解有限.
- 描述YOMSA对于改善诊断和患者护理至关重要.
研究的目的:
- 为了评估YOMSA患者的临床特征.
- 评估YOMSA的疾病过程和预后.
- 为了确定影响YOMSA生存的因素.
主要方法:
- 来自梅奥诊所网站 (1998-2021) 的医疗记录的回顾性审查.
- 诊断出YOMSA的患者的鉴定.
- 临床特征,自主功能测试和生存数据的分析.
主要成果:
- 在1496例MSA病例中确定了20名YOMSA患者;中位数发病年龄为39.1岁,男性为65%.
- 最常见的亚型是MSA-帕金森症. 平均存活时间为8.3年.
- 与运动发作症状相比,初始自主性衰竭发作预测了不利的生存率 (HR=2.89,P=0.04).
结论:
- 在现型和预后方面,YOMSA在很大程度上反映了典型的MSA.
- 对YOMSA的诊断往往会被推迟.
- 症状发作时的自主性失败是YOMSA生存的显著负预后指标.
相关概念视频
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Myasthenia Gravis: Diagnostic Tests
831
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
831
COPD: Pathogenesis and Clinical Features
272
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
272
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188


